Share Price:

APNASPENAspen Pharmacare Hldgs14675175 (1.21%)

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

Press Releases

Renewal of Cautionary Announcement

Shareholders are referred to the cautionary announcement released by Aspen on 4 February 2013 (and subsequent renewals of this cautionary announcement) in which shareholders were advised of discussions between Aspen and MSD, known as Merck in the United States and Canada, in respect of a possible transaction comprising the acquisition of an active pharmaceutical ingredient facility situated primarily in the Netherlands and a related portfolio of pharmaceutical finished dose form products. These discussions remain ongoing and may have a material effect on the price of Aspen’s securities if successfully concluded and accordingly shareholders are advised to continue exercising caution when dealing in Aspen’s securities. Durban 3 June 2013

Read More

Aspen Trading Statement

APN – Aspen Pharmacare Holdings Limited – Trading statement Aspen Pharmacare Holdings Limited (Incorporated in the Republic of South Africa) (Registration number 1985/002935/06) Share code: APN & ISIN: ZAE000066692 (“Aspen”) Trading statement Aspen shareholders are hereby advised that, diluted normalised headline earnings per share (“DNHEPS”) from continuing operations, headline earnings per share and earnings per share for the 6 months ended 31 December 2012, are expected to exceed those reported in the comparative period, ended 31 December 2011, within the following ranges: Measure Range Notes DNHEPS from continuing operations  21% to 25% 1  Headline earnings per share  15% to 19% 2 Earnings per share  5% to 9% 3 Notes: 1. DNHEPS from continuing operations comprises diluted headline earnings per share adjusted for transaction costs, restructure costs and foreign exchange movements on transaction accounting. DNHEPS is the primary measure used by management to assess Aspen’s underlying operating performance. 2. The growth in headline earnings per share has been diluted by the effect of an increase in the weighted average number of ordinary shares in issue as a consequence of the conversion of 17.6 million preference shares into an equivalent number of ordinary shares on 28 June 2012. 3. The growth in earnings per share has been diluted as a result of capital profits on the disposal of discontinued businesses and products in the prior year and the effect of an increase in the weighted average number of ordinary shares in issue as a consequence of the conversion of 17.6 million preference shares into an equivalent number of ordinary shares on 28 June 2012. The financial results on which this trading announcement is based have not been reviewed or reported on by Aspen`s external auditors. Aspen`s interim results for the 6 months ended 31 December 2012 are scheduled to be published on SENS on 7 March 2013. Durban 21 February 2013 Sponsor: Investec Bank Limited

Read More

Cautionary Announcement – Discussions with MSD

ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) Registration number 1985/0002935/06 Share code: APN ISIN: ZAE000066692 (“Aspen” or “the Company”) CAUTIONARY ANNOUNCEMENT – DISCUSSIONS WITH MSD Shareholders are advised that Aspen is currently engaged in discussions with MSD (known as Merck in the United States and Canada) in respect of a possible transaction comprising the acquisition of an active pharmaceutical ingredient facility situated primarily in the Netherlands and a related portfolio of pharmaceutical finished dose form products. These discussions may have a material effect on the price of Aspen’s securities if successfully concluded and accordingly shareholders are advised to exercise caution when dealing in the company’s securities. Durban 4 February 2013 Sponsor Investec Bank Limited

Read More
Accolades

Stephen Saad named as Business Leader of the Year

STEPHEN SAAD AWARDED BUSINESS LEADER OF THE YEAR TITLE Johannesburg: Aspen Group Chief Executive, Stephen Saad, was named as the Business Leader of the Year at the annual Sunday Times Top 100 Companies banquet last night. Durban-based Stephen, who graduated from the University of Natal in 1986 with a B.Com and later qualified as a Chartered Accountant, said: “We had a vision and we have pursued it with both perseverance and passion. I hope that our story inspires future generations of entrepreneurs. There is a wealth of opportunities to be harnessed both in and from South Africa. The rewards transcend material and personal benefits because the true dividends come from making a meaningful difference, uplifting people and helping them achieve goals that they believed were beyond their capability. Collectively we can deliver a better future for all South Africans.” Saad (48), co-founded Aspen Healthcare together with Gus Attridge, Aspen’s Group Deputy Chief Executive, and two other members in 1997. Since its establishment, Aspen has become the world’s ninth largest generic pharmaceutical company and Africa’s largest pharmaceutical manufacturer. Aspen is also the leading pharmaceutical company in South Africa, sub-Saharan Africa and Australia and a world leading manufacturer of generic anti-retrovirals (ARVs). With 18 manufacturing facilities at 13 sites on 6 continents, Aspen’s sustained unbroken performance of over 40% compound growth per annum of all key financial indicators has seen its share price from inception rise from 53c to over R156 at the time of the award. “Aspen’s success can be attributed to a number of factors, most notably innovation and leadership that practices a fine balance between passion and logic. Perseverance is a core quality at Aspen and our teams passionately embrace obstacles as challenges and deliver irrespective of the circumstances. We are also exceedingly proud of our South African manufacturing expertise and proved conventional wisdom wrong by showing that we can produce high quality products locally for global export,” said Saad. Aspen’s internationalisation has resulted in more than half of the Group’s revenue and profits being generated offshore and the success achieved in Australia following the acquisition of the Sigma pharmaceutical business in 2011 attests to astute leadership given that Aspen Australia’s profit has increased by many multiples in 18 months. Stephen said “one of Aspen’s greatest achievements of the past year was exporting Nelson Mandela Day internationally through our subsidiaries, with more than 2000 employees from 11 countries contributing to the success of 29 projects on 6 continents which touched the lives of some 3000 beneficiaries.” Through Aspen’s rapid global expansion strategy, the Group now employs 6000 people and has a presence in South Africa, Australia, Hong Kong, Philippines, Kenya, Tanzania, Uganda, Dubai, Germany, Ireland, Mauritius, Brazil, Mexico and Venezuela. Aspen supplies high quality, affordable medicines and products to more than 150 countries around the world. Stephen has driven Aspen’s Corporate Social Investment initiatives which focus on supporting programmes targeting the delivery of primary healthcare in rural areas, HIV/AIDS and TB programmes and healthcare education. In 2012 he raised more than R10 million for paediatric healthcare in Africa by cycling more than 240km off road in one day, an initiative that was supported by Minister of Health, Dr Aaron Motsoaledi. Stephen describes his overriding vision as: “Perseverance pays as to rest is to rust”. He is married and has four daughters.

Read More

Aspen’s revenue increases by 23%

JSE Ltd listed Aspen Pharmacare Holdings Limited (APN), Africa’s largest pharmaceutical manufacturer, has announced pleasing results for the year ended 30 June 2012, extending its record of growth for a fourteenth consecutive year. Group Performance Revenue from continuing operations rose by 23 percent to R15.3 billion. Operating profit from continuing operations increased by 25 percent to R3.9 billion. Normalised headline earnings from continuing operations, being headline earnings from continuing operations adjusted for restructuring costs, transaction costs and a foreign exchange gain on transaction funding, increased by 22% to R2.9 billion. Normalised diluted headline earnings per share from continuing operations rose 22 percent to 636.2 cents. A capital distribution of 157 cents per ordinary share (2011: 105 cents) by way of a capital reduction payable out of share premium. Stephen Saad, Aspen Group Chief Executive said, “During the year Aspen increased its diversity in product offerings and geographic exposure. The Group’s positive performance was led by exceptional growth in the Asia Pacific business, while the International business and the Sub-Saharan Africa business also achieved strong gains. The South African business had a positive second half, but consistent with previously communicated expectations, showed negative growth for the year as a whole.” South African Business The South African business returned to growth in the second half, as projected. A number of well-documented once-off factors unfavourably influenced results, particularly in the first six months of the year. The effect of the difficult first half is evident in full year revenue being 2% lower at R6.2 billion and operating profit before amortisation, adjusted for specific non-trading items (“EBITA”), being down 9% at R1.8 billion. Revenue in the Pharmaceutical division was up 9% in the second half resulting in the full year revenue coming in flat at R5.2 billion. This creditable result was achieved against a backdrop of a strike, government procurement of anti-retrovirals (“ARVs”) from donors in preference to accessing the awarded tender and the two biggest products in the Pharmaceutical division, Seretide and Truvada, facing generic competition for the first time. These set-backs were mitigated over the course of the year through Aspen’s success with Foxair, the generic of Seretide and by the launch of Tribuss, the first generic once-a-day triple combination ARV in South Africa. Furthermore, with the depletion of the donor funds, the tender offtake regularised in the second half of the year. Profit margin percentages were reduced for the year, affected by energy costs and wage inflation rising considerably more rapidly than the 2.14% increase in the single exit price granted by the Department of Health. Lower pricing in the ARV tender also contributed to the margin squeeze. Fortunately Aspen managed to offset most of the margin pressure through efficiency gains in production. The Consumer division suffered a contraction in revenue of 11% to R1.0 billion. The major factor was the expiry towards the end of the 2011 financial year of the license with Pfizer for a range of infant milk products, which contributed approximately R250 million to revenue on an annual basis. Growth of over 20% in Aspen’s infant milk brand, Infacare, has been effective in reducing the impact of the reversal. The Group has continued to invest in capital projects to upgrade and expand production capabilities in Port Elizabeth and in East London. A major refurbishment of the active pharmaceutical ingredient facility at the Fine Chemicals business in Cape Town is also underway. Asia Pacific business The Asia Pacific business, bolstered by the acquisition of the Sigma pharmaceutical business in Australia in the second half of the 2011 financial year, delivered exceptional results. This region has increased its contribution to Group revenue from 23% to 37%. Revenue doubled to R6.0 billion and EBITA grew by 128% to R1.5 billion. The business acquired from Sigma has been fully integrated with Aspen’s pre-existing business in Australia. Synergies have been gained in the establishment of a single business platform. Further benefits have come through reduced cost of goods which have been realised by taking advantage of Aspen’s competitive manufacturing and procurement competencies. Aspen Philippines commenced trade during the year and has approximately 100 sales personnel actively deployed. International Business The International business recorded a 3% reduction in revenue to R2.5 billion, but nevertheless raised EBITA by 28% to R0.9 billion. Customer sales in Latin America increased 11% to R1.0 billion buoyed by strong performances in Brazil and Venezuela. In Mexico sales were flat, but revenue was sacrificed to third party distributors of global brands in the balance of the territory. The overall reduction in revenue in the International business was as a consequence of the transitioning of certain global brands to third party distributors and the elimination of low margin sales to third parties. Profit margins benefitted from the ongoing projects to reduce the cost of goods of global brands. Sub-Saharan Africa business In Sub-Saharan Africa, gross revenue increased by 27% to R1.7 billion and EBITA improved 40% to R248 million. Growth in profit was achieved by each of the three elements of the business. The GSK Aspen Healthcare for Africa collaboration advanced revenue strongly with increased representation and new product launches. The Shelys operation, based in East Africa, achieved excellent margin gains through improved business efficiency. Exports into the region also increased. Prospects Aspen has withstood the challenges of the last year and has remained the top supplier of medicines in South Africa. One in four prescriptions dispensed in the country in the private sector is for an Aspen product. The Group’s leadership position in the public sector was endorsed with the recent award of the oral solid dose tender with Aspen once again receiving the largest allocation of 25%. The benefits of a strong product pipeline will see increased growth momentum in the 2013 financial year. A number of legislative changes remain under consideration by the regulator, including international benchmarking and the capping of logistics fees. The timing and consequences of the resolution of these matters remain uncertain. The South African government’s policy decision to support domestic manufacturers in

Read More

Aspen Trading Statement

APN – Aspen Pharmacare Holdings Limited – Trading statement Aspen Pharmacare Holdings Limited (Incorporated in the Republic of South Africa) (Registration number 1985/002935/06) Share code: APN & ISIN: ZAE000066692 (“Aspen”) Trading statement Aspen’s shareholders are hereby advised that diluted normalised headline earnings per share from continuing operations, headline earnings per share (“HEPS”) and earnings per share, for the 12 months ended 30 June 2012, are expected to exceed those reported in the comparative period, ended 30 June 2011, by the following ranges: Measure Range Notes Diluted normalised HEPS from continuing operations 18% to 24% 1 HEPS 21% to 27% Earnings per Share 4% to 10% 2 Notes: 1. Diluted normalised HEPS from continuing operations comprises diluted HEPS from continuing operations adjusted for transaction costs, restructure costs and foreign exchange gains on transaction accounting. 2. The growth in earnings per share has been reduced as a result of capital profits on the disposal of discontinued businesses and products in the present year being lower than in the prior year. The financial results on which this trading announcement is based have not been reviewed or reported on by Aspen`s external auditors. Aspen`s audited results for the year ended 30 June 2012 are scheduled to be published on SENS on 12 September 2012. Durban 30 August 2012 Sponsor: Investec Bank Limited

Read More

Aspen Global acquires Australian product portfolio for R2.2 billion

The Aspen Group (“Aspen”) is pleased to announce that Aspen Global Incorporated (“Aspen Global”), a wholly owned subsidiary of Aspen Holdings, has reached agreement with GlaxoSmithKline plc (“GSK”) for the acquisition of a portfolio of 25 established pharmaceutical products (“the Products”) which are distributed in Australia (“the Transaction”). The Transaction consideration is GBP 172 million (ZAR 2.2 billion at ZAR 12.72/GBP) based upon a completion date of 31 October 2012 and is subject to minor reduction should completion be delayed beyond this date. The Transaction is subject to the following conditions precedent: The approval of the Australian competition authorities; and The approval of the Australian Foreign Investment Review Board. The effective date of the Transaction will be the last business day of the calendar month in which the last of the applicable conditions precedent is fulfilled. Existing manufacturing arrangements for the Products will be assumed by Aspen Global. Aspen Global intends to appoint Aspen Australia to distribute the Products. Funding The Transaction will be funded from new offshore debt facilities. Arrangements for the raising of the new debt have been settled, but remain subject to documentation being completed. Financial effects The unaudited pro-forma financial effects set out in the tables below have been prepared to assist Aspen Holdings shareholders to assess the impact of the Transaction on the earnings per share (“EPS”) and diluted EPS, headline EPS (“HEPS”) and diluted headline EPS, diluted normalised HEPS and the net asset value (“NAV”) and the tangible NAV (“NTAV”) per Aspen Holdings ordinary share as at 31 December 2011 and for the interim period then ended. It has been assumed for the purposes of the pro-forma financial effects that the Transaction took place with effect from 1 July 2011 for Statement of Comprehensive Income purposes and at 31 December 2011 for Statement of Financial Position purposes. The pro-forma financial effects have been prepared for illustrative purposes only and, because of their nature, they may not fairly present Aspen’s restated financial position at 31 December 2011 and the restated results of its operations for the six months then ended. The Directors of Aspen Holdings are responsible for the preparation of the financial effects which have not been reviewed by the auditors. The “After” columns represent the effects after the Transaction. The “Change %” columns compares the “After” columns to the “Before” columns. The number and weighted average number of shares in issue have been stated net of treasury shares. Notes: Extracted from the published interim financial statements for the six months to 31 December 2011. The figures for the Products were derived from the unaudited management accounts of GSK for the six months ended 31 December 2011 and the audited financial statements of GlaxoSmithKline Holdings Pty Ltd for the year ended 31 December 2011. A preliminary assessment has indicated that the intellectual property relating to the Products constitutes indefinite life assets which have been fairly valued in accordance with future expected performance and hence no amortisation has been provided for in the pro-forma financial effects above. Non-recurring transaction costs of R72 million are included in determining the financial effects of which R48 million has been capitalised. The remaining R24 million is excluded in determining the impact of the Transaction on diluted normalised HEPS and represents the only adjustment to diluted HEPS in determining diluted normalised HEPS. Notional interest for the six months ended 31 December 2011 has been provided based on the costs of financing the Transaction. The Products The Products comprise long established pharmaceutical brands of proven performance. The main areas of therapeutic treatment of the Products are analgesic, antibiotics, anti-virals and the central nervous system. Other areas covered include anti-nauseant, anti-inflammatory and muscle relaxants. The leading Products are well recognised brands including Amoxil, Augmentin, Imigran, Kapanol, Lamactil, Mesasal, Timentin, Valtrex, Zantac and Zofran. The Products which are the subject of the Transaction recorded revenue of AUD 127.4 million during the year ended 31 December 2011. During that period Valtrex came off patent and faced generic competition which has subsequently intensified. Some of the Products have also been subject to the Australian Government’s mandatory annual price cuts based on competitive discounting to pharmacy. These price reductions are likely to continue resulting in the revenue expected to be generated by the Products declining over time. The impact of these factors is illustrated by the Products generating revenue in the six months to 30 June 2012 of AUD 47.4 million (six months to 30 June 2011: AUD 70.2 million). Rationale The Products acquired through the Transaction represent an excellent fit with Aspen’s existing portfolio and the added revenue will strengthen Aspen’s position as one of the leading pharmaceutical companies in Australia. Whilst the Products received little promotional focus from GSK, Aspen is confident that it will be able to leverage its proven ability to reinvigorate older brands and the Products’ considerable brand equity in order to enhance the value of the portfolio. Aspen expects the Transaction to be earnings accretive in the year ending 30 June 2013. Small Related Party Transaction GSK is an 18.6% shareholder of Aspen Holdings and is a related party to Aspen Holdings in terms of the JSE listings requirements. BDO Corporate Finance (Pty) Ltd, as the independent professional expert, has confirmed that the value of the Transaction is fair to the shareholders of Aspen Holdings and their fairness opinion is available for inspection at Aspen Holdings’ registered office for a period of 28 days from the date of this announcement. Durban 15 August 2012 Sponsor: Investec Bank Limited The Standard Bank of South Africa Limited Sole Underwriter and Mandated Lead Arranger

Read More

Judy Dlamini, Aspen Chairman’s Upper Echelon interview

“I actually want to work until the very last day of my life”, Judy Dlamini ALEC HOGG: Upper Echelon is brought to you by Deloitte – for innovative thinking and thorough strategic planning turn to Deloitte. In our Upper Echelon this week, Judy Dlamini, chair of Mbekani Investment Holdings and better known through her chair of Aspen Pharmacare, one of the hottest stocks on the JSE. In fact, since 2007 when you took over as chair there, Judy, the share price has just gone one way and that’s up. That’s always a good thing, one of the top 20 companies in South Africa. I guess that you were made for it though, given that you are a medical doctor by training and then moved into investment banking, then into entrepreneurship but let’s go back a little bit. Going through your CV I saw Vryheid came up there, Vryheid High or certainly the fact that you did your high schooling there, how did that work in? JUDY DLAMINI: Actually interesting that you could dig that out, it’s an interesting story, I met my husband when I was at Marianhill High School and the plan was that I would do matric at Marianhill High School but the nuns were not too happy with me going out with my husband then. They had this system that they would say you can come back to do matric but we just need your dad to come so that we can talk to him and my dad was very strict. So I went back home, I said, dad, I don’t want to go back there, the maths is not so great. So my dad the whole of November, December he was looking for a school and he found Vryheid, so that’s how I ended up there. ALEC HOGG: That’s incredible, which school in Vryheid? JUDY DLAMINI: Vryheid State High School, not Inkamana because it was so late, the application was quite late and you get space but not for a maths and science class. I used to say to my dad it’s maths or nothing because I knew what maths could do for you. ALEC HOGG: That’s a fabulous story and, of course, your husband Sizwe Nxasana is well known in his own right but you’ve been a little bit in his shadow, Judy. It was interesting to look through here, Discovery Holdings, you were on their board, I guess when there was a split with FirstRand, they might have felt [they] didn’t really want a competitor to be on the board and I guess it’s in your family, you must be one and the same? JUDY DLAMINI: Not really, that’s not how it worked out. I just felt that I had too much on my plate. So every five years I actually look at the portfolio and then I’ll actually say no, I need to come off this board and focus on other things. So that was the reason really and I love low profile, I guess it’s just the personality. Maybe it’s the medical training, doctors are more your one on one people than people who love the podium. ALEC HOGG: What took you out of medicine into investment banking first and then into the entrepreneurial environment? JUDY DLAMINI: I wanted to be a doctor from the age of four, I always wanted to be a doctor and I loved it but I lost the passion, maybe because there was crime involved in my practice and something in me died. Maybe also I just felt I wanted more, I just needed my brain to be stimulated more. As a medical doctor I just felt that your view in life tends to be a bit myopic and then I decided to go to business school and did an MBA, which broadened the horizon, it actually…you know a little bit of something in every field, which for me was ideal. Ja, so the losing of passion was good because then it actually broadened the way I view things. ALEC HOGG: And ignited new passions. JUDY DLAMINI: Oh yes. ALEC HOGG: Business, growing up was it something that did appeal to you? JUDY DLAMINI: I had this focus of being a medical doctor but on the side there was the element of business because my father wasn’t highly educated, actually he had hardly any education but he was an entrepreneur, he ran his small painting contractor company and maybe from that. My mother was a primary school teacher, which is actually just streamline professional but my father is, I guess, where I got the business and the entrepreneurial keenness from. ALEC HOGG: How do you and Sizwe get this life balance or work-life balance? I asked him the same question, when we spoke a little while ago, in this same series of Upper Echelon, I’d love to hear your input? JUDY DLAMINI: We make the effort, Alec. You have to make the effort, you never get the balance right but we try, we always try. I was just talking earlier on that last week he had a meeting in London and I organised my diary that I actually joined him so that we had two extra days to spend with each other. We just take the time to spend with each other and also with [our] children. So let’s just say it’s our priority, it’s the main priority, family and then work. ALEC HOGG: It hasn’t been all plain sailing, we were all very saddened when Sifiso passed away. Was there anything in his passing, your son, that has maybe changed the way you look at things? I ask this because I share that experience as well and it’s not something that easily sits with one, they never go away and it is a… JUDY DLAMINI: It doesn’t, it’s still very fresh as you can imagine and I’ve had a lot of pain in the past, it’s just the worst. ALEC HOGG: Judy, but the contribution

Read More

Media Enquiries

Shauneen Beukes
Group Communications Consultant
+27 31 580 8600
+27 82 389 8900
sbeukes@aspenpharma.com

Share on social

Follow on social

Closed Period

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.

Corporate

Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.

View our teams below: